What is the most likely cannabis reform under a second Trump term?

Most analysts believe the SAFER Banking Act, which allows cannabis businesses access to financial services, has the highest chance of passing. Following that, a Department of Justice-led rescheduling of cannabis to Schedule III is seen as a plausible executive action that would provide major tax relief.

How would rescheduling to Schedule III help cannabis businesses?

Moving cannabis to Schedule III would remove the crippling 280E tax code provision. This allows state-legal cannabis businesses to deduct standard business expenses (rent, payroll, marketing) like any other company, dramatically improving profitability and stability.

Does 'states' rights' mean cannabis would become federally legal?

No. A states' rights approach typically means the federal government would choose not to enforce prohibition in states that have legalized it. Cannabis would remain federally illegal, but the conflict would be de-prioritized, providing safety and operational clarity for state programs.

What should a cannabis business do to prepare for potential federal changes?

Businesses should ensure their state-level compliance is impeccable, as any federal reform will likely reward well-regulated operators. They should also engage with banking partners who are prepared to pivot, and consult with accountants familiar with 280E to be ready for potential tax code changes.

Trump Cannabis Industry Policy 2026: A Surprising Opportunity?

The scent of potential change is in the air, and for once, it’s not just coming from a freshly opened jar of Gelato. In the wake of the 2024 election, a complex and counterintuitive sentiment is taking root within the cannabis industry: cautious optimism for the Trump administration’s second term. While the relationship has historically been fraught, a confluence of political pragmatism, overwhelming state-level success, and sheer economic force is creating what many advocates see as a genuine, if fragile, pathway to federal reform. The evolving Trump cannabis industry policy 2026 landscape is becoming a top discussion in boardrooms from Oakland to Boston.

The Unlikely Catalysts for Change

Let’s be blunt: the cannabis community didn’t rally behind Trump in 2024. The memory of former Attorney General Jeff Sessions rescinding the Cole Memo still stings. So why the shift in outlook? It boils down to three hard-to-ignore realities that even a politically unconventional administration must eventually address.

The 38-State Mandate

First and foremost is the undeniable weight of the states. As of April 2026, 38 states have robust medical cannabis programs, and 24 have legalized adult use. That’s over 75% of the nation living where cannabis is legal in some form, including deep-red states like Florida, Ohio, and Montana. This isn't a coastal fringe movement anymore; it's a mainstream American policy. The federal-state conflict creates a regulatory nightmare for businesses and a safety risk for consumers. The pressure to resolve this dissonance is bipartisan and overwhelming.

Economic Imperatives and Banking Hurdles

The second catalyst is pure dollars and sense. The legal cannabis market is projected to surpass $45 billion in annual sales by 2026, yet it operates largely in cash due to the federal banking blockade via 280E tax code. This is a public safety issue and a massive economic inefficiency. A Republican administration traditionally attuned to business and banking interests may find the push for the SAFER Banking Act—which has already passed the Senate multiple times—an easy win. It’s a targeted reform that doesn’t require full legalization but would stabilize the entire industry overnight.

Potential Pathways to Reform

So, how could a second Trump term actually move the needle? Insiders are watching two primary avenues, each with varying degrees of likelihood.

The DeScheduling Directive

The most powerful tool would be a Department of Justice-led review of cannabis scheduling via the Controlled Substances Act. The President can direct the Attorney General and the DEA to initiate this process. Given the FDA’s prior recommendation to reschedule cannabis to Schedule III (a move still pending from the previous administration), a directive to complete a swift, evidence-based review could be framed as simply finishing the job. Schedule III would not create a federally legal adult-use market, but it would eviscerate the crushing 280E tax burden, allowing businesses to deduct standard expenses and instantly become more profitable and competitive.

States' Rights as a Unifying Banner

This is where the political narrative gets interesting. A “states' rights” approach to cannabis could be a powerful unifying message for a Trump administration. Framing federal non-interference as respecting the will of individual state voters could attract support from libertarian-leaning Republicans and placate social conservatives by not imposing a national legalization model. This could manifest as an updated, more permanent version of the Cole Memo, instructing federal agencies to stand down in states with regulated programs. Seedbanks like North Atlantic Seed Co. operating in multiple states would gain immense clarity and security.

Lingering Concerns and Wild Cards

Of course, optimism is tempered with caution. The industry remembers the whiplash of the first term. Key concerns include: - Appointments: Who will be the next Attorney General or DEA Administrator? A hardline pick could freeze all progress. - Enforcement Priorities: Will the administration target large, multi-state operators while leaving small businesses alone, or vice versa? - International Treaties: The UN's drug control treaties remain a complicating factor for any administration pursuing full legalization.

The wild card? Public opinion. National support for legalization has solidified at over 70%. For an administration focused on its legacy and electoral success, aligning with such a popular position in a second term, free from re-election concerns, might be an attractive proposition.

What This Means For You

Whether you’re a patient, a casual consumer, or an aspiring cultivator, this shifting political wind matters. For consumers, a move to Schedule III or a stronger states' rights policy means safer, more consistent products as companies invest more in quality and innovation—think better testing and new product forms. For medical patients, it legitimizes their treatment and could spur more research. For entrepreneurs and workers, it means access to banking, fairer taxation, and the ability to build a stable career without the constant fear of federal intervention. It could mean finally being able to write off your lights or your payroll.

The bottom line? The Trump cannabis industry policy 2026 conversation is no longer just about resistance. It’s about navigating a real, if unpredictable, opportunity. The industry has matured into an economic and political force that cannot be ignored. While no one is expecting a presidential blunt rotation, the pragmatic pressures of the market and the electorate might just force the most significant federal cannabis reform in history. Stay tuned, stay engaged, and as always, know your source.

Cannabis Industry's Cautious Optimism for Trump's Second Term